The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the signaling of interleukin (IL)-31.

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...

Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...

Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...

in patients with moderate-to-severe atopic dermatitis and adults with prurigo nodularis, respectively," Galderma said in a Friday press release. The drug is also approved in the U.S. and is under ...

A new medicine, Nenolizumab, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat two ...